A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice

Ophthalmologica

Volumn 225, Issue 2, 2011, Pages 112-119

  Monés, Jordi ^a  

^a CENTRO MÉDICO TEKNON   (Spain)

Author keywords

Age related macular degeneration; ANCHOR; EXCITE; MARINA; PIER; PrONTO; Ranibizumab; SUSTAIN

Indexed keywords

RANIBIZUMAB;

DISEASE ACTIVITY; EXUDATIVE MACULAR DEGENERATION; FOLLOW UP; HUMAN; MEDICAL PRACTICE; PATIENT CARE; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT RESPONSE; VISION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EXUDATES AND TRANSUDATES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77957727640     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319906     Document Type: Review

References (13)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degenerat ion. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248.
4. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG: A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-1739.
5. Mones J, for the EXCITE Study Group: Safety and tolerability of two dosing regimens of ranibizumab in patients with subfoveal choroidal neo-vascularisation secondary to age-related macular degeneration: outcomes of the EXCITE study. 25Ith Meeting of the Club Jules Gonin, St Moritz, 2008.
6. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R, on behalf of the EXCITE study group: Visual acuity responses in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial (abstract 2374). Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, 2009.
7. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
8. Holz FG, Meyer C, Eter N, on behalf of the SUSTAIN study group: Safety and efficacy of ranibizumab treatment in patients with neovascular age-related macular degeneration: 12-month results of the SUSTAIN study (abstract 3095). Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, 2009.
9. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G: Results of one year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409-413.
10. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-1747.
11. Verbraak F, Schlingemann R, Mitchell P, Holz F, Inhoffen W, Weichselberger A: SUSTAIN study: evaluating visual acuity recovery after a single ranibizumab re-treatment in patients with neovascular AMD. 9th Euretina Congress, Nice, 2009.
12. Singer M, Wong P, Wang P-W, Scott L: HORIZON extension trial of ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): two-year safety and efficacy results (abstract 3093). Invest Ophthalmol Vis Sci 2009;50.
13. Spaide R: Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-680.